Mach7 Technologies Ltd. (AU:M7T)
ASX:M7T
Want to see AU:M7T full AI Analyst Report?
M7T Stock Chart & Stats
AU$0.56
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.56
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.25 - AU$0.69
Previous CloseN/A
Volume428.94K
Average Volume (3M)368.13K
Market Cap
AU$71.68M
Enterprise ValueAU$60.81M
Total Cash (Recent Filing)AU$18.49M
Total Debt (Recent Filing)AU$1.75M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Sep 01, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding235,009,720
10 Day Avg. Volume349,234
30 Day Avg. Volume368,134
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)1.74
Price to Sales (P/S)2.35
P/FCF Ratio701.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.36Price Target Upside-36.61% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.26
Revenue Forecast (FY)AU$28.03M
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Market TractionA 75.5% year-over-year revenue increase signals durable market traction for Mach7's imaging software. Sustained top-line growth supports scale economics, enables reinvestment in product and sales, and increases the probability of achieving operating leverage and long-term margin improvement.
Low Leverage / Strong Balance SheetA low debt-to-equity ratio and healthy equity base provide financial flexibility over months to years. Limited leverage reduces solvency risk, allows cash conservation for product development or strategic M&A, and cushions the company during cyclical downturns without immediate financing needs.
Enterprise-focused Software / Sticky OfferingsFocusing on enterprise medical imaging and deep integrations with hospital systems creates high switching costs and sticky customer relationships. This enterprise positioning supports recurring revenue, multi-year contracts, and potential platform expansion across radiology/cardiology workflows over time.
Bears Say
Persistent Negative ProfitabilityOngoing negative EBIT and net margins indicate the company has yet to convert revenue growth into sustainable profits. Persisting losses constrain retained earnings, limit internal funding for scaling, and may require external capital or structural margin improvements to achieve durable shareholder returns.
Volatile Cash GenerationRecent declines and volatility in free cash flow and weak conversion of income to operating cash reduce financial predictability. This undermines the firm's ability to self-fund growth, increases reliance on financing, and raises execution risk for multi-quarter investments in sales, R&D, or integrations.
Limited Scale / Small TeamA small employee base constrains product development velocity, global sales coverage, and customer support for large health systems. Limited scale can slow feature delivery, hamper competitive responses to larger rivals, and extend the time needed to convert market opportunities into stable revenue streams.
Mach7 Technologies News
M7T FAQ
What was Mach7 Technologies Ltd.’s price range in the past 12 months?
Mach7 Technologies Ltd. lowest share price was AU$0.24 and its highest was AU$0.69 in the past 12 months.
What is Mach7 Technologies Ltd.’s market cap?
Mach7 Technologies Ltd.’s market cap is AU$71.68M.
When is Mach7 Technologies Ltd.’s upcoming earnings report date?
Mach7 Technologies Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 82 days.
How were Mach7 Technologies Ltd.’s earnings last quarter?
Mach7 Technologies Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.024 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.019.
Is Mach7 Technologies Ltd. overvalued?
According to Wall Street analysts Mach7 Technologies Ltd.’s price is currently Overvalued.
Does Mach7 Technologies Ltd. pay dividends?
Mach7 Technologies Ltd. does not currently pay dividends.
What is Mach7 Technologies Ltd.’s EPS estimate?
Mach7 Technologies Ltd.’s EPS estimate is -0.03.
How many shares outstanding does Mach7 Technologies Ltd. have?
Mach7 Technologies Ltd. has 235,009,720 shares outstanding.
What happened to Mach7 Technologies Ltd.’s price movement after its last earnings report?
Mach7 Technologies Ltd. reported an EPS of -AU$0.024 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Mach7 Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:M7T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mach7 Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.36 (-36.61% Downside)
AU$0.36 (-36.61% Downside)
Blogger Sentiment
Bullish
AU:M7T Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$249.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.50%
12-Months-Change
Fundamentals
Return on Equity
-23.86%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Mach7 Technologies Ltd.
Mach7 Technologies Limited delivers sophisticated solutions for managing, storing, and facilitating the exchange of medical imaging data within healthcare organizations across the globe, including North America, Asia Pacific, the Middle East, and Europe. Their offerings include enterprise diagnostic viewing tools like the eUnity enterprise and diagnostic viewers, which simplify image access. The company also provides comprehensive data management solutions that enable workflows across various departments and entire enterprises to capture, index, manage, store, distribute, view, exchange, and analyze clinical imaging and multimedia content. Additionally, Mach7 offers its Enterprise PACS imaging platform and a suite of professional services, covering implementation, training, ongoing support, maintenance, and project supervision. Founded in 1977, the company maintains its headquarters in South Burlington, Vermont.
M7T Company Deck
M7T Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a constructive operational pivot: management presented a clear strategic reset, measurable cost reductions (payments down 9% YoY, 6% QoQ), stronger cash flow (positive operating cash flow in Q2), a stable ARR run rate of $23M, and early commercial/product milestones (first Flamingo customer, CE certificate). These positives are tempered by a near-term reduction in CARR of $2.9M (removal of the NTP project), the strategic exit from the VHA program that reduced backlog but improves long-term margin prospects, lingering VNA/KLAS performance work that may take 12–24 months to fully resolve, and a CTO search following the CIO departure. Overall, the highlights (stabilized ARR, improved cash and cost discipline, new product momentum and regulatory/market expansion) outweigh the lowlights, although several improvements will take time to flow through revenue.View all AU:M7T earnings summariesM7T Stock 12 Month Forecast
Average Price Target
AU$0.36
▼(-36.61% Downside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Beamtree Holdings Ltd
―
Artrya Limited
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---